RxDoctor Payments Data

Walid Abdallah, MD

Ophthalmology · Rockford, ILNPI 1871912717

Payments from drug & device makers

$9,680in general payments, 2019–2025

Across 209 payments — averaging $46.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Regeneron$1K
  • AbbVie$637
  • Oyster Point Pharma, Inc.$637
  • Mallinckrodt Hospital Products Inc.$554
  • Bausch & Lomb Americas Inc.$529
  • plus $4K from 16 others

What the payments were for

  • Consulting fees$1,37514%
  • Food & beverage$8,30586%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,680 in reported general payments places this provider in the 85th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$966,425
Medicare patients
1,326
Services billed
6,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine201$166,134
Cyclosporine232$104,050
XiidraLifitegrast68$56,326
Prednisolone Acetate1,017$36,996
LumiganBimatoprost73$28,957
CequaCyclosporine37$23,585
EysuvisLoteprednol Etabonate34$16,442
ProlensaBromfenac Sodium43$14,986
Ketorolac Tromethamine616$14,856
SimbrinzaBrinzolamide/Brimonidine Tart64$12,322
Latanoprost895$11,169
TyrvayaVarenicline Tartrate12$8,839
CombiganBrimonidine Tartrate/Timolol24$7,969
Ofloxacin483$6,024
Alphagan PBrimonidine Tartrate29$5,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$637$209,046327 claims
Bausch & Lomb Americas Inc.Xiidra$529$56,32668 claims
Sun Pharmaceutical Industries Inc.Cequa$320$23,58537 claims
AlconSimbrinza$2,137$12,32264 claims
Oyster Point Pharma, Inc.Tyrvaya$637$8,83912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →